Valneva SE Missed Consensus Estimates

Valneva SE (VALN) reported a loss of $0.40 per share on revenue of $40.62 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.28 per share on revenue of $42.62 million. The company missed consensus estimates by 42.86% while revenue fell 25.93% compared to the same quarter a year ago.

Valneva SE is a specialty vaccine company. It is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva SE is based in Saint-Herblain, France.